Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common stock
-
Shares outstanding
-
47.1M
-
Number of holders
-
64
-
Total 13F shares, excl. options
-
13.8M
-
Shares change
-
-63.6K
-
Total reported value, excl. options
-
$94.2M
-
Value change
-
-$902K
-
Put/Call ratio
-
0.03
-
Number of buys
-
33
-
Number of sells
-
-25
-
Price
-
$6.84
Significant Holders of Whitehawk Therapeutics, Inc. - Common stock (WHWK) as of Q2 2023
77 filings reported holding WHWK - Whitehawk Therapeutics, Inc. - Common stock as of Q2 2023.
Whitehawk Therapeutics, Inc. - Common stock (WHWK) has 64 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 13.8M shares
of 47.1M outstanding shares and own 29.2% of the company stock.
Largest 10 shareholders include Avoro Capital Advisors LLC (2.85M shares), ACUTA CAPITAL PARTNERS, LLC (1.85M shares), Alerce Investment Management, L.P. (1.63M shares), BlackRock Inc. (1.02M shares), BAKER BROS. ADVISORS LP (990K shares), VANGUARD GROUP INC (762K shares), JANUS HENDERSON GROUP PLC (532K shares), Decheng Capital Management III (Cayman), LLC (526K shares), Soleus Capital Management, L.P. (333K shares), and GEODE CAPITAL MANAGEMENT, LLC (333K shares).
This table shows the top 64 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.